EXPORT CITATION

Chapter-063 Lixisenatide: A Cardiodiabetes Perspective

BOOK TITLE: Cardiodiabetes Update: A Textbook of Cardiology

Author
1. Panikar Vijay
2. Vadgama Jimit
3. Kamat Tejas
ISBN
9789352703043
DOI
10.5005/jp/books/14130_64
Edition
1/e
Publishing Year
2018
Pages
3
Author Affiliations
1. KG Somaiya Medical College, Mumbai, Maharashtra, India, KJ Somiaya Medical college; Lilavati Hospital, Mumbai, Maharashtra, India, Mumbai, Maharashtra, India, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India, Lilavati Hospital, Mumbai, Maharashtra, India, Lilavati Hospital, Mumbai, India
2. Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India, Thyroid and Hormone Clinic, Surat, Gujarat, India, Swaminarayan Diabetes, Thyroid and Hormone Clinic, Surat, Gujarat, India
3. Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India, Lilavati Hospital, Mumbai, Maharashtra, India, Diabetes Care, Panaji, Goa, India
Chapter keywords
Lixisenatide, dipeptidyl peptidase-4, DPP4, acute coronary syndrome, ACS, type 2 diabetes mellitus, T2DM, glucagon-like peptide-1 receptor agonist, GLP-1RA, cardiovascular, CV

Abstract

Lixisenatide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1RA) with a plasma half-life of 1.5–4.5 hours. It is a potent and selective GLP-1RA action and is more resistant to proteolysis by dipeptidyl peptidase-4 (DPP4) than native GLP-1 with a binding affinity that is approximately 4 times greater than human GLP-1 hormone. These factors collectively enable once-a-day dosing of lixisenatide. Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) was a randomized, double-blind, placebo controlled, parallel-group, and multicenter phase III event driven trial that assessed the effects of lixisenatide added to standard T2DM therapy on cardiovascular (CV) morbidity and mortality in patients with a recent acute coronary syndrome (ACS).

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved